May 30th 2025
The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.
The trial plans to enroll approximately 70 patients with mCRPC.
Campbell emphasized that although gender representation in medicine is shifting, structural and cultural biases continue to influence academic recognition.
Overall, 59% of patients achieved at least a 50% decline in PSA level.
This year's meeting with feature several notable sessions in prostate cancer, bladder cancer, kidney cancer, and other GU malignancies.
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
The company plans to submit a Biologics License Application to the FDA at the end of 2026.
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
Further follow-up and additional treatments in the study are ongoing.
Subcutaneous nivolumab approved in EU, Canada for solid tumors
The approvals are supported by findings from the phase 3 CheckMate-67T trial.
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
These data are intended to support a new drug application to the FDA in the second half of 2025.
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
The single-use test can deliver diagnostic results for chlamydia and gonorrhea in approximately 30 minutes.
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
Clarifying CPT 52353 billing for same-side stone cases
Jonathan Rubenstein, MD, and Mark Painter tackle a coding question for treating stones.
Expert discusses the promise of emerging MISTs for BPH
James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
Jared S. Winoker, MD, addresses the wide range of stone burdens treated by the CVAC system for the study.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
The committee voted 4-5 in opposition of a favorable benefit-risk profile.
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
The phase 3 study design will now be submitted for final review by the agency.
Study shows value of precision-based approaches in prostate cancer
The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
Urologic surgeons successfully complete world’s first bladder transplant
The bladder transplant procedure involved a collaboration between the University of California, Los Angeles and the University of Southern California.
Patient selection for cytoreductive nephrectomy in 2025
"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
SBRT may offer a safe alternative to CFRT after prostatectomy
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy
Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.
Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Published data support safety, efficacy of vaginal insert for SUI
Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
Enrollment progresses in study for cisplatin-induced hearing loss in testicular cancer
ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.
Long-term data point to durable efficacy of Optilume for urethral strictures
The freedom from re-intervention rate was 71%.
MRI and focal therapy may enable men on AS to safely delay surgery or radiation
Use of focal therapy was shown to prolong the duration of active surveillance.
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation
ORIC-944 shows promise in combination with AR inhibitors in mCRPC